Are requirements for GMP compliance, in fact, less stringent for API manufacturers versus dosage form manufacturers: less validation, less cleaning validation, less detailed documentation? Is there any basis for individuals to interpret Q7A this way?

Q7A recognizes that there are fundamental differences between the manufacturing processes for
API and Drug Products. GMPs are no less important in API processing. GMPs are applied
differently to APIs because of the nature of API manufacturing and the differences in API
manufacturing.